|
Post by celo on Jun 28, 2023 9:50:26 GMT -5
Mannkind feeling the effects of all the weight loss diabetic drugs getting a ton of press? I guess there will be less overweight individuals therefore there will be less diabetics. I don't get the drawdown but here we are...
|
|
|
Post by peppy on Jun 28, 2023 10:22:41 GMT -5
Mannkind feeling the effects of all the weight loss diabetic drugs getting a ton of press? I guess there will be less overweight individuals therefore there will be less diabetics. I don't get the drawdown but here we are... Insulin puts weight on. Afrezza market is type one. MNKD volume at 2 hours of trade...... low volume, real time, 404,226 shares summary, 404,465 Avg. Volume 3,212,409 $3.94. -0.03 (-0.7557%) Off topic ... sayhey24 Regarding type two. I have been listening to you tube. Here is the point. Talk that type two is marked by hyperinsulinemia. Too much insulin in the blood. Fat in the liver. Opposite of what Al was saying Sayhey?
|
|
|
Post by mymann on Jun 28, 2023 10:53:26 GMT -5
Picked the wrong horse to bet on.
|
|
|
Post by prcgorman2 on Jun 28, 2023 10:56:59 GMT -5
normal rinse and repeat volatility
|
|
|
Post by mymann on Jun 28, 2023 11:09:06 GMT -5
Mnkd horse with broken leg, Lqda horse on steroids. SP should be reversed.
|
|
|
Post by peppy on Jun 28, 2023 11:19:32 GMT -5
Mnkd horse with broken leg, Lqda horse on steroids. SP should be reversed. schrts.co/IewtsvQR
|
|
|
Post by awesomo on Jun 28, 2023 11:32:10 GMT -5
Mnkd horse with broken leg, Lqda horse on steroids. SP should be reversed. MNKD market cap: $1.04B LQDA market cap: $0.61B That just shows how shares outstanding matters for share price, and why authorizing 400M more shares could cast a pall over the share price appreciation even if the company becomes more valuable.
|
|
|
Post by peppy on Jun 28, 2023 11:38:33 GMT -5
Mnkd horse with broken leg, Lqda horse on steroids. SP should be reversed. MNKD market cap: $1.04B LQDA market cap: $0.61B That just shows how shares outstanding matters for share price, and why authorizing 400M more shares could cast a pall over the share price appreciation even if the company becomes more valuable. That and over head resistance.... the I am even now, get me out. MNKD has has 20 years of over head (resistance).... MNKD Monthly. schrts.co/tHmpzmPULQDA IPO'ed in 2018. scroll up.
|
|
|
Post by mymann on Jun 28, 2023 13:10:23 GMT -5
400,000,000 shares, just in case of hostile take over. Few more years of job security and paycheck for the Mike.
|
|
|
Post by mymann on Jun 28, 2023 13:12:19 GMT -5
Selling for tax purposes. Wink, wink.
|
|
|
Post by caesar on Jun 28, 2023 13:15:12 GMT -5
"Rest & Grow" requires patience for investors who are watching their stake in this concern "Rest & Shrink".
Not bitching, but getting concerned that the management team is unable to convince Wall Street to peg the PPS above $5/share.
The sub $4 is enough to give one the Summertime Blues.....
|
|
|
Post by prcgorman2 on Jun 28, 2023 14:46:37 GMT -5
"Rest & Grow" requires patience for investors who are watching their stake in this concern "Rest & Shrink". Not bitching, but getting concerned that the management team is unable to convince Wall Street to peg the PPS above $5/share. The sub $4 is enough to give one the Summertime Blues..... FYI - "Rest & Grow" was never said by MannKind management. There's a thread with a post from @radgray (I believe) that proved "Rest & Grow" was literally a mistaken transcription. The PPS is what it is. The healthcare sector is down in 2023.
MNKD is down more substantially more than the sector, but it's MNKD. Profitability, and fundamentals are the way out of this. Some people on this board are saying LQDA is a good investment, but I think those comments are an intentional distraction (and belong on the LQDA board or in a LQDA thread).
|
|
|
Post by peppy on Jun 28, 2023 15:09:33 GMT -5
MNKD Nasdaq summary volume, 1,843,732 (almost half that volume the last half hour.) Avg. Volume 3,212,409
$3.96. -0.01 (-0.25%)
|
|
|
Post by cretin11 on Jun 28, 2023 16:20:25 GMT -5
"Rest & Grow" requires patience for investors who are watching their stake in this concern "Rest & Shrink". Not bitching, but getting concerned that the management team is unable to convince Wall Street to peg the PPS above $5/share. The sub $4 is enough to give one the Summertime Blues..... Not long ago we were speculating that once we got above $5 we would be out of Pennystock Land, more funds would jump in, we'd be off and running, etc. There were even some who said "$5 is our new floor" yet here we are in the $3s. Those who chose to hedge with a stake in LQDA have at least mitigated their MNKD losses. Rest & Grow requires the "Grow" part of the equation. Your suggestion Rest & Shrink seems more accurate, or maybe Rest & Dilute. It can be discouraging, but you'll be assured by some that it has nothing to do with our management team but instead is due to factors totally beyond our company's control. Time will tell.
|
|
|
Post by cedafuntennis on Jun 28, 2023 16:41:08 GMT -5
You are a bit disingenuous, in the sense that we are growing as a company and growing quite well. Afrezza may not be growing by leaps and bounds, but DPI is growing at a tremendous rate and that translates directly to the bottom line in royalties, manufacturing, manufacturing cost per unit, etc.
|
|